Eli Lilly and Co. (LLY) said Thursday it has entered an agreement with the Bill & Melinda Gates Foundation to ensure access to Lilly's COVID-19 antibody therapy for low- and middle-income countries. The agreement is part of the COVID-19 Therapeutics Accelerator, an initiative launched by the Gates Foundation, Wellcome and Mastercard. The therapy will be manufactured at the Fujifilm Diosynth Biotechnologies facility in Denmark, where the accelerator has reserved manufacturing capacity. "Lilly has already started the manufacturing technology transfer at risk, in anticipation of regulatory authorization for its antibody therapy," the partners said in a statement. "In the interest of making supply of COVID-19 therapeutic innovations available globally as quickly as possible, Lilly will make certain volumes of its antibody therapeutic manufactured in other facilities available to lower-income countries prior to April 2021, pending the timing of regulatory authorization." Lilly shares were up 2.2% premarket, and have gained 13.3% in the year to date, while the S&P 500 has gained 5.8%.
-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
October 08, 2020 07:00 ET (11:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.